articleThe Lancet OncologySep 21, 2020BRONZE OA

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

TPThomas PowlesMSMichiel S. van der HeijdenDCDaniel CastellanoMDMatthew D. GalskyYLYohann Loriot

Queen Mary University of London · Dutch Cancer Society · +36 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

494
total citations
FWCI
67.02
Percentile
100%
References
25
Citations per year

Authors

227

Topics & keywords

Keywords
  • Durvalumab
  • Medicine
  • Tremelimumab
  • Chemotherapy
  • Metastatic Urothelial Carcinoma
  • Oncology
  • Open label
  • Internal medicine
No related works found for this paper.

Funding